Patents by Inventor Nicolas RASCHE

Nicolas RASCHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy utilizing DNA alkylating agents and ATR inhibitors
    Patent number: 12616750
    Abstract: The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: May 5, 2026
    Assignee: Merck Patent GmbH
    Inventors: Carl Deutsch, Birgit Piater, Nicolas Rasche, Heike Dahmen, Frank Zenke, Astrid Zimmermann, Marcel Rieker
  • ANTI-PROTAC ANTIBODIES AND COMPLEXES
    Publication number: 20250312468
    Abstract: Mono or bi-specific antibodies, antibody fragments, or fusion proteins thereof, are capable of binding to the VHL ligand degrading moiety (degron) of a proteolysis targeting chimera (PROTAC) and, optionally, to a target protein. Complexes (PAX) of such antibodies, antibody fragments, fusion proteins thereof, and PROTACS are also capable of. Methods for their production can be performed, and these antibodies have medical and non-medical uses.
    Type: Application
    Filed: July 1, 2022
    Publication date: October 9, 2025
    Applicant: Merck Patent GmbH
    Inventors: Marcel RIEKER, Sebastian Jaeger, Nicolas Rasche, Doreen Koenning, Christian Schroeter, Hendrik Schneider
  • ANTI-GD2 ANTIBODIES, IMMUNOCONJUGATES AND THERAPEUTIC USES THEREOF
    Publication number: 20250186603
    Abstract: The invention provides antibodies which bind human GD2 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 8, 2023
    Publication date: June 12, 2025
    Inventors: Sean D. MCKENNA, Alec GROSS, Jianguo MA, Julia DOTTERWEICH, Nicolas RASCHE, Min SHAN, Christiane AMENDT, Jan ANDERL, Willem SLOOT
  • ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF
    Publication number: 20250179210
    Abstract: The invention provides antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 9, 2023
    Publication date: June 5, 2025
    Inventors: Jan ANDERL, Stefan HECHT, Nicolas RASCHE, Stephan DICKGIESSER, Min SHAN, Carl DEUTSCH, Willem SLOOT, Sabine RAAB-WESTPHAL, Felix HART, Lars TOLEIKIS, Nir BERGER
  • METHODS AND TOOLS FOR CONJUGATION TO ANTIBODIES
    Publication number: 20250170268
    Abstract: The present invention relates to antibodies comprising tags that can be covalently conjugated to the primary amino group of a linker in the presence of a microbial transglutaminase. Also provided by the invention are methods for producing an antibody-linker-conjugate by mixing an antibody with a linker and a microbial transglutaminase. Also provided are antibody-linker conjugates and antibody-drug-conjugates producible according to the inventive method and a kit of parts comprising a buffer and a microbial transglutaminase.
    Type: Application
    Filed: March 9, 2023
    Publication date: May 29, 2025
    Inventors: Stephan DICKGIESSER, Nicolas RASCHE, Marcel RIEKER
  • Cysteine engineered antigen-binding molecules
    Patent number: 11623963
    Abstract: A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is according to the IMGT, and wherein the antibody Fc region does not comprise an antigen-binding CH3 domain; and an ABM conjugate (ABMC) comprising the ABM and at least one heterologous molecule covalently conjugated to one or both of the cysteines at positions 108 and 113 of the CH2 domain.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 11, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Gordana Wozniak-Knopp, Florian Rüker, Gerhard Stadlmayr, Jakub Rybka, Nicolas Rasche, Stephan Dickgiesser
  • COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS
    Publication number: 20210369705
    Abstract: The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 2, 2021
    Applicant: Merck Patent GmbH
    Inventors: Carl DEUTSCH, Birgit PIATER, Nicolas RASCHE, Heike DAHMEN, Frank ZENKE, Astrid ZIMMERMANN, Marcel RIEKER
  • CYSTEINE ENGINEERED ANTIGEN-BINDING MOLECULES
    Publication number: 20200277399
    Abstract: A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is according to the IMGT, and wherein the antibody Fc region does not comprise an antigen-binding CH3 domain; and an ABM conjugate (ABMC) comprising the ABM and at least one heterologous molecule covalently conjugated to one or both of the cysteines at positions 108 and 113 of the CH2 domain.
    Type: Application
    Filed: October 3, 2018
    Publication date: September 3, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Gordana WOZNIAK-KNOPP, Florian RÜKER, Gerhard STADLMAYR, Jakub RYBKA, Nicolas RASCHE, Stephan DICKGIESSER